Myeloproliferative neoplasms (MPNs) feature a malignant clone containing the JAK2 V617F mutation, or another mutation causing dysregulated JAK2 kinase activity. The multiple disease phenotypes of MPNs, and their tendency to transform phenotypically, suggest pathophysiologic heterogeneities beyond a common phenomenon of JAK2 hyperactivation. JAK2 has the potential to activate multiple other signaling molecules, either directly through downstream effectors, or indirectly through induction of target gene expression. We have interrogated myeloproliferative signaling in myelofibrosis (MF) and secondary acute myeloid leukemia (sAML) patient samples using mass cytometry, which allows the quantitative measurement of multiple signaling molecules simultaneously at the single-cell level, in cell populations representing a nearly complete spectrum of hematopoiesis. MF and sAML malignant cells demonstrated a high prevalence of hyperactivation of the JAK-STAT, MAP kinase, PI3 kinase and NFκB signaling pathways. Constitutive NFκB signaling was evident across MF and sAML patients. A supporting gene set enrichment analysis (GSEA) of MF showed many NFκB target genes to be expressed above normal levels in MF patient CD34+ cells. NFκB inhibition suppressed colony formation from MF CD34+ cells. This study indicates that NFκB signaling contributes to human myeloproliferative disease and is abnormally activated in MF and sAML.
INTRODUCTION
Myeloproliferative neoplasms (MPNs) are characterized by a common pathogenic mechanism: hyperactivation of the JAK2 kinase, most frequently as a result of the JAK2 V617F mutation. 1, 2 JAK2 V617F and other mutations leading to JAK2 hyperactivation are common among polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF, either primary or secondary). The phenotypic diversity of MPNs, however, implies other pathogenic mechanisms besides excessive JAK2 activity. Although differences between PV and ET have been associated with mutant JAK2 homozygosity (predominantly in PV, albeit not rare in ET and MF), and with greater IFNγ-STAT1 target gene expression in ET versus PV, 3 the pathogenic mechanisms that distinguish MF and secondary acute myeloid leukemia (sAML) remain poorly understood.
In this study, multiple myeloproliferative intracellular signaling molecules were quantified in MF and sAML patient samples via mass cytometry, a technology that enables the detection of ⩾ 30 metal-tagged antibodies with single-cell resolution. 4 This enables quantitative study of signaling abnormalities in a nearly complete spectrum of hematopoietic cell populations. [4] [5] [6] [7] [8] [9] Antibody panels were designed to (1) identify immunophenotypic cell populations throughout myeloid differentiation, whose intracellular signaling could be abnormal in MF or sAML, and (2) interrogate myeloproliferative signaling pathways with previously reported abnormalities in other myeloid neoplasms. [10] [11] [12] [13] [14] [15] JAK2 hyperactivation is the known common signaling abnormality underlying PV, ET and MF. [16] [17] [18] [19] [20] [21] It is the primary known consequence of mutations in JAK2, MPL, SH2B3 (LNK) and CALR, found in the majority of human MPN clones. 15, [21] [22] [23] [24] JAK2 not only signals through its direct substrates STAT3 and STAT5 but can also collaterally activate a number of other signaling pathways; notably, the MAP kinase, PI3 kinase and NFκB signaling pathways (Supplementary Figure S1 ). 25 This study measures the activities of multiple effectors in these pathways via mass cytometry ( Supplementary Table S1 ). Mutations in genes outside the JAK-STAT pathway, particularly in genes encoding epigenetic factors, are abundant in MF and sAML. 1, 25, 26 Furthermore,~50% of post-JAK2 V617F-MPN sAMLs lack the JAK2 mutation. 27 By implication, these sAMLs are either not driven by JAK2 hyperactivity, or else achieve JAK2 hyperactivity by an alternative mechanism for which mutant JAK2 is dispensable. Therefore JAK2 dysregulation is unlikely to be the only signaling abnormality present in MF and sAML.
NFκB hyperactivation has previously been observed in a subset of de novo AMLs, 12, 28, 29 particularly those of the FLT3-ITD subtype, 13 and in myelodysplastic syndromes. 14 In MF, multiple cytokines are present systemically at supranormal levels, including several that can activate NFκB signaling non-cell-autonomously. 30, 31 The present study establishes the widespread prevalence of NFκB hyperactivation in MF and sAML. NFκB hyperactivation in MF and sAML could occur via both cellautonomous signaling downstream of active JAK2 and non-cellautonomous activation by cytokines.
MATERIALS AND METHODS

Patient samples
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(PB mononuclear cells or BM mononuclear cells) were obtained by Ficoll gradient extraction and cryopreserved according to standard procedures. Clinical and genetic information for patients studied (16 MF, 10 sAML) is included in Supplementary Table S2 . Variant allele frequency was obtained for the JAK2 V617F mutation by quantitative PCR. 32 A total of 12 MF patients (7 JAK2 V617F-positive) and 10 sAML patients (6 JAK2 V617Fpositive) were included in mass cytometry experiments in this study, with four additional MF patients included in colony forming unit assays only. Healthy controls for these experiments are listed in Supplementary  Table S3 .
Targeted gene sequencing
A custom capture panel was designed for targeted sequencing of singlenucleotide variants and exons in genes known or predicted to be associated with MPN or AML pathogenesis. The first set of patients was analyzed using a custom capture array from Roche NimbleGen (Madison, WI, USA) with additional capture probes from Integrated DNA Technologies (Coralville, IA, USA) as described previously. 33 Capture probes for additional single-nucleotide variant and exon targets (as listed in Supplementary Table S4 ) were added for a second round of sequencing. Sequencing was done on the Illumina HiSeq2000 and HiSeq2500 platforms according to the manufacturer's recommendations (Illumina Inc, San Diego, CA, USA). Variant detection and validation was performed as previously described. 33 Potential pathogenic mutations were identified for a subset of patients ( Supplementary Table S2 ).
Cell treatment with cytokines and/or signaling inhibitors
Conditions were derived from prior mass cytometry signaling studies of healthy human BM. 4 Briefly, cryopreserved cells were thawed into RPMI containing 10% fetal bovine serum, heparin (20 U/ml, Sigma, St. Louis, MO, USA), and benzonase (25 mU/ml, Sigma) and labeled with cisplatin (2.5 μM, Enzo Life Sciences, Farmingdale, NY, USA) in serum free RPMI. 34 Cisplatintreated cells were incubated in serum-containing RPMI for 30 min, followed by 1 h incubation in the presence or absence of inhibitor (5 μM ruxolitinib or 2 μM IKK inhibitor VII), followed by 15 min stimulation with cytokine and subsequent fixation and staining. Stimulation conditions in the screening experiment ( Figure 1 ) were: basal (unstimulated); ruxolitinib, thrombopoietin (TPO, 50 ng/ml); TPO plus ruxolitinib, granulocyte colony stimulating factor (G-CSF, 20 ng/ml); and sodium pervanadate (125 μM 
Mass cytometry
Cell staining for mass cytometry was performed as described previously, 4 using antibody panels described in Supplementary Table S1 . Samples for the screening experiment ( Figure 1 ) were mass-channel barcoded, pooled and stained as a single sample, with signals read on a CyTOF1 mass cytometer (DVS/Fluidigm, South San Francisco, CA, USA) using a debarcoder program to identify individual samples. 5, 35, 36 For later experiments (Figures 2-5), samples were stained in batches in individual tubes, and readouts were recorded on a CyTOF2 mass cytometer (DVS/ Fluidigm). Data were analyzed in Cytobank (cytobank.org), including both conventional cell population gating ( Supplementary Figures S2-S4 ), and cell clustering via SPADE. 9 Gating for subpopulations of HSPC (hematopoietic stem and progenitor cells) is shown in Supplementary Figure S4 , emulating gates previously validated by xenotransplantation. 37 Statistical analysis of mass cytometry signaling data For statistical analysis of patient sample signaling readouts versus normal controls across multiple experiments ( Figure 3 ), signal medians were normalized to the mean of the median values of the normal controls within the experiment. Thereby deviation beyond the normal range could be identified. Where multiple experiments utilized samples from the same patient sample collection, the sample from the experiment containing the higher average normal basal median for the given signaling antibody readout was selected for statistical analysis, thereby giving a more conservative statistical analysis from the overall dataset ( Figure 3 ) than from any individual experiment. Density Resampled Estimate of Mutual Information (DREMI) analysis ( Figure 3g and Supplementary Figure S16 ) was performed as previously described. 38 Gene set enrichment analysis (GSEA) for MF CD34+ HSPC Gene set enrichment analysis was performed as previously described. 39 Published expression data from MF and healthy control CD34+ cells was downloaded from Gene Expression Omnibus (http://www.ncbi.nlm.nih. gov/geo/, series GSE53482). 40 NFκB target genes were curated from online databases and published literature, 29, 41 and divided into three groups corresponding to canonical and AML-related targets, pro-apoptotic targets, and nonspecific targets, which were assessed both individually and combined ( Supplementary Table S5 ).
Plasma cytokine analysis
PB plasma collected under standard protocols was stored at − 80°C. Concentrations of 30 cytokines/chemokines were analyzed in duplicate using the Meso Scale Discovery platform with the V-PLEX human cytokine 30-plex kit (Meso Scale Discovery, Rockville, MD, USA).
Colony forming unit (CFU) assays
Colony forming unit assays were performed in semisolid culture using Methocult H4035 (StemCell Technologies, Vancouver, BC, Canada), containing G-CSF, GM-CSF, IL-3, SCF, and supplemented with TPO (10 ng/ml). Lineage-negative (Lin-) CD34+ cells were sorted from normal control BM or MF patient PB (see Supplementary Tables S1 and S2 for individual patient information; Supplementary Figure S5 for gating) and cultured in Methocult H4035, with or without ruxolitinib, IKKiVII, and/or TNFα, as described in Figure 8 .
RESULTS
Dysregulated myeloproliferative signaling across early myeloid differentiation
In an initial screening experiment, BM mononuclear cells from three healthy controls and four MF patients, plus PB mononuclear cells from five sAML patients were analyzed by mass cytometry ( Supplementary Tables S2 and S3 ). Samples were stained with antibodies labeling 13 cell surface markers and 17 markers of intracellular signaling, cell division or apoptosis ( Supplementary  Table S1 ). Signaling was analyzed in live, non-apoptotic PB mononuclear cells/BM mononuclear cells utilizing the SPADE (Spanning tree Progression of Density normalized Events) clustering algorithm, 9 Figure S10) . In contrast to cytokine hypersensitivity of STAT5 phosphorylation, constitutively high IκBα levels generally showed little to no reduction after 1 h incubation with the JAK inhibitor ruxolitinib (Figure 1d and Supplementary Figure S11 ).
On the basis of gating derived from xenotransplant studies, 37,42 HSPC could be subdivided into immunophenotypic cell populations representing myeloid differentiation from a hematopoietic stem cell-enriched population (CD34+, CD38 − , CD90+ and CD45RA − ), to lineage-committed blasts (Supplementary Figures  S3 and S4 ). Abnormal constitutive signals in MF and sAML patients frequently spanned this entire spectrum of myeloid differentiation (Figure 1e and Supplementary Figure S12 ).
NFκB hyperactivity in MF and sAML HSPC Constitutively elevated IκBα levels suggested the hypothesis that the NFκB pathway is dysregulated in MF and sAML. Therefore, a direct measure of NFκB activation, phosphorylated NFκB subunit p65/RELA, was included in all subsequent experiments. Signaling was measured basally and in the presence of tumor necrosis factor (TNFα) and/or the IκB kinase inhibitor IKKiVII, to stimulate or inhibit the NFκB pathway, respectively. In experiments on primary patient samples and controls, phosphorylation of S529 of p65/RELA was utilized as the measure of NFκB activation ( Supplementary  Table S1 ). Experiments using the JAK2 V617F mutant human erythroleukemia (HEL) cell line demonstrated cooperativity and interdependence between p65/RELA phosphorylation on S529 by Casein Kinase II and phosphorylation on S536 by IκB kinases (Supplementary Figure S13 ). The p-S529 antibody was preferred in patient samples due to more robust signal in response to TNFα, and potential competition between the two antibodies for a limited pool of activated p65/RELA (data not shown).
Supranormal levels of phosphorylated p65/RELA were observed in unstimulated HSPC (9/12 MF and 6/8 sAML above normal range; Figures 2a-c and 3a ). In addition, stimulation with TNFα induced p65/RELA phosphorylation above levels observed in healthy controls (4/12 MF patients, 6/8 sAML; Figures 2a and b and 3b ). Therefore the NFκB pathway was both constitutively active and hypersensitive in patients' HSPC. One hour incubation with IKKiVII inhibited both basal and TNFα stimulated p65/RELA phosphorylation, while a similar incubation with ruxolitinib did not (Figures 2a  and b and Supplementary Figures S13 and S14 ). Longer ruxolitinib incubations of up to 12 hours produced only minor inhibition of basally elevated p65/RELA phosphorylation, as compared with synchronous incubation without ruxolitinib (Supplementary Figure S15 ). Patients with elevated basal p65/RELA phosphorylation invariably exhibited this abnormality throughout the spectrum of myeloid differentiation (Figure 2c ).
MF HSPC exhibited higher basal phosphorylation of p65/RELA NFκB (in 9/12 patients), compared with the normal BM control population (Figure 3a ). The majority of sAML patients (6/8) also exhibited basally elevated phosphorylation of p65/RELA in HSPC, with significant differences observed between MF and sAML patient populations and controls. The highest levels were observed in JAK2 V617F mutant MF patients, being significantly higher than levels observed in JAK2 wild-type MF patients, which were also significantly higher than normal controls. TNFαstimulated p65/RELA phosphorylation was not significantly different in the overall MF patient population versus controls (Figure 3b ), although several patients (4/12 MF patients, 6/8 sAML) exhibited a much greater positive deviation from the average experiment-matched control than did any normal control. sAML patients overall and JAK2 V617F mutant sAML patients specifically showed significant elevation of TNFα stimulated p65/RELA phosphorylation. Basal IκBα, while substantially elevated in several individual patients (3/16 MF and 1/10 sAML patients above the normal range observed in all experiments, Figure 3c ; in contrast to 2/4 MF and 3/5 sAML above the normal range observed in the screening experiment, Figures 1a and e ), was not significantly elevated in the overall patient populations (Figure 3c ).
Basal and TPO-stimulated STAT5 phosphorylation values were substantially above the normal control range in several individual patients (basal: 4/16 MF and 2/10 sAML above normal range; TPOsimulated: 5/16 MF and 3/10 sAML above normal range), but these elevations fell short of statistical significance in all populations except JAK2 wild-type MF (Figures 3d and e ). JAK2 wild-type sAML patients exhibited significantly lower TPO-stimulated pSTAT5 values than normal controls (Figure 3e ), hinting at possible negative feedback on TPO-stimulated JAK2 activation by an active downstream signal. The overlapping ranges of patient versus control pSTAT5 values may reflect more rapid turnover of STAT5 phosphorylation as compared with p65/RELA phosphorylation, thus minimizing basal levels, and/or potentially the use of a response-saturating dose of activating cytokine (based on responses derived from normal BM 4 ). Although NFκB activation parameters did not differ by allele burden in JAK2 mutant patients (not shown), there was a significant correlation both among MF patients and in the combined MF plus sAML patient group between median basal p-p65/RELA and pSTAT5 levels (Figure 3f ). At the single-cell level within individual patients, the DREMI 38 conditional probability algorithm was used to estimate the relative difference in predictive value of cellular pSTAT5 on cellular p-p65/RELA. DREMI scores for patient samples, estimating the relative predictive value of TPO stimulated pSTAT5 on p-p65/RELA, were significantly higher in MF and sAML patient sets than normal controls (Figure 3g and Supplementary Figure S16 ).
Phosphorylation of p38, a MAP kinase pathway target, which can also be activated by TNFα, was significantly elevated in MF HSPC versus both controls and sAML HSPC (Figure 3h ). Phosphorylation of CREB, a MAP kinase pathway target, which can be activated downstream of JAK2 (Supplementary Figure S1) , was elevated in MF patient HSPC both basally and in response to TPO (Supplementary Figure S18 ; validation of SPADE analysis 4, 9 shown in Supplementary Figure S17 ).
Elevated p-p65/RELA in MF and sAML was observed not only in HSPC, but also in other hematopoietic cell populations (Figure 4 ; similar to IκBα, Supplementary Figure S10 , contrast with pCREB, Supplementary Figure S18 ; for SPADE analysis 4, 9 validations, see Supplementary Figures S7 and S17 ). T cells showed significant elevation of basal p-p65/RELA in both MF and sAML, as well as significantly higher levels in JAK2 V617F mutant versus JAK2 wildtype MF (Figure 4c ). Elevation of basal p-p65/RELA in B cells and monocytes was observed in both MF and sAML samples, but was more prevalent in sAML, while hypersensitivity of monocytes to TNFα appeared specific to sAML (Figures 4d-f ). Activation of p65/RELA phosphorylation by TNFα, however, was confined to HSPC and monocytes, in patient and control samples ( Figures  5a and b and Supplementary Figures S19-S21 ).
MF and sAML patients studied by mass cytometry exhibited elevated plasma levels of TNFα (Figure 5c ), suggesting that NFκB hyperactivation may be in part non-cell-autonomous, driven by TNFα. To explore this possibility, TNFα expression was examined by mass cytometry in MF patient samples ( Figure 6 ). AML HSPC have been reported to express TNFα, which can activate NFκB non-cell-autonomously. 29 In MF as well as normal control blood, TNFα expression was principally observed in monocytes (Figure 6a ). Both monocytes and Lin-CD34+ HSPC, however, exhibited higher TNFα expression than normal controls, both basally and in response to nonspecific stimulation with PMA +ionomycin (Figures 6b-d) . These findings indicate the potential for NFκB hyperactivation in HSPC to be induced non-cellautonomously by TNFα. To test the potential role of JAK2 V617F in TNFα overproduction, TNFα levels in supernatants from BaF3/ MPL cells retrovirally expressing empty vector, wild-type JAK2, or JAK2 V617F, were measured (Figure 6e ). BaF3/MPL cells expressing JAK2 V617F produced significantly more TNFα than cells expressing empty vector or wild-type JAK2.
Aberrant NFκB pathway target gene expression in MF
Recent studies have profiled gene expression in MF HSPC and granulocytes. 21, 40, 43 We utilized several published NFκB target gene sets 29, 41 to construct a tiered gene list for querying expression data for an NFκB target enrichment profile in MF ( Supplementary Table S5 ). The Tier 1 list comprised wellestablished NFκB target genes, particularly those observed to be upregulated in AML subtypes. 29, 41, [44] [45] [46] [47] This set was subdivided into Tier 1a, excluding pro-apoptotic gene targets associated with TNFα-FAS activation, and Tier 1b, which constituted pro-apoptotic NFκB target genes. Tier 2 included established but nonspecific NFκB target genes, which are also known expression targets of other signaling pathways. Using these categories, a published data set of gene expression in CD34+ cells from MF patients versus normal controls 40 was queried.
In MF patient (n = 42) versus normal BM (n = 15) CD34+ cells, there was a trend toward greater expression of NFκB target genes, particularly the more specific Tier 1 gene set (false discovery rate (FDR) q = 0.084, family-wise error rate (FWER) P = 0.041; Figure 7a ). Both pro-apoptotic (Tier 1b) and non-pro-apoptotic (Tier 1a) NFκB target genes were overexpressed in MF versus normal CD34+ cells (Figure 7a and Supplementary Table S6 ). A few NFκB target genes were, contrarily, downregulated in MF versus normal CD34+ cells ( Figure 7b) ; however, these did not coincide with the proapoptotic Tier 1b genes (Figure 7a ). JAK2 mutant MF patients (n = 23) showed stronger enrichment versus controls (n = 15) of the Tier 1 gene set (FDR q = 0.078; FWER P = 0.039) than did JAK2 wild-type patients (n = 19; FDR q = 0.17; FWER P = 0.083; Supplementary Figure S22 and Supplementary Table S6 ). The pro-apoptotic Tier 1b gene set was particularly enriched in the JAK2 mutant MF patients versus controls (FDR q = 0.029; FWER P = 0.015 Supplementary Figure S22 and Supplementary Table S6 ) and versus JAK2 wild-type patients (FDR q = 0.048; FWER P = 0.024; Figure 7c and Supplementary Table S6 ). In contrast, non-proapoptotic Tier 1a NFκB target genes were not clearly enriched in JAK2 mutant versus JAK2 wild-type MF patients (Figure 7c and Supplementary Table S6 ). The less specific Tier 2 and the combined Tier 1+2 gene sets were also significantly enriched in JAK2 mutant versus wild-type patients ( Supplementary Table S6 and Supplementary Figure S22) . Overall, the majority of NFκB target genes were overexpressed in CD34+ cells from all MF patients versus controls; however, enrichment of pro-apoptotic NFκB target genes was most pronounced in JAK2 mutant MF patients.
NFκB pathway inhibition reduces myeloid colony formation
To assess the contribution of NFκB activity to myeloproliferation, cell growth and colony formation assays were performed using IKKiVII alone or in combination with ruxolitinib. Growth of JAK2 V617F mutant human erythroleukemia cells was inhibited by either IKKiVII or ruxolitinib, and the combination of IKKiVII plus ruxolitinib produced enhanced inhibition (Supplementary Figure S23 ). In colony forming assays, IKKiVII inhibited colony formation from MF patient CD34+ cells similarly to ruxolitinib, and the combination of IKKiVII and ruxolitinib produced a combinatorial inhibitory effect (Figure 8a and Supplementary Figure S24) . Colony numbers were also reduced in the presence of TNFα; however, colony formation was almost entirely eliminated by IKKiVII and/or ruxolitinib in the presence of TNFα. Similar inhibitory effects of IKKiVII and/or ruxolitinib were observed on normal CD34+ cells (Figure 8b ). However, individual MF patients with pronounced NFκB hyperactivition (MF9, MF10 and MF16: see Figure 2c and Supplementary Figure S20) were those with the strongest inhibitory responses to IKKiVII and/or TNFα (Figure 8a and Supplementary Figure S24a) .
DISCUSSION
Intracellular flow cytometry has been used previously to identify and describe signaling dysregulations in hematopoietic cancers. 10, 11, 15, 48, 49 We have extended this approach to MF and sAML using mass cytometry, based on the hypothesis that MF and sAML likely possess intracellular signaling phenotypes beyond the canonical JAK-STAT pathway. Indeed, the NFκB, MAP kinase, and PI3 kinase pathways, as well as the JAK-STAT pathway, exhibited constitutive signal activation and hypersensitivity to cytokine stimulation. Among these pathways, the NFκB pathway showed the greatest statistical deviation from normal over the MF and sAML patient groups studied. While measures of NFκB hyperactivation appeared most pronounced in JAK2 V617F mutant MF, NFκB hyperactivation was also evident in both JAK2 mutant and non-mutant MF and sAML. Consistent with this evidence, increased expression of NFκB pathway target genes was identified in an independently published MF gene expression dataset, 40 in both JAK2 mutant and non-mutant MF patients. Elevated plasma TNFα levels were observed in almost all of the patients examined, consistent with previous studies on MF patients. 30, 31 Data from colony forming unit assays suggest that NFκB activity is essential for myeloproliferation both normally and in MF. Therefore we hypothesize that NFκB activity is an intrinsic component of myeloproliferation, which is heightened in MF and sAML.
NFκB pathway hyperactivation is a novel finding in MPNs and sAML, although it has previously been reported in a subset of de novo AMLs, including but not exclusively the FLT-3 ITD subtype, 12, 13, 28, 29 and in myelodysplastic syndromes. 14 JAK2mutant MPN and FLT-3 ITD AML have in common an activating kinase mutation in the malignant clone, which may be a cause of NFκB hyperactivation. Consistent with this notion, correlation between STAT5 and p65/RELA phosphorylation was observed in MF and sAML. An activating kinase mutation can lead to NFκB pathway activation by two basic mechanisms: cell autonomously from signaling downstream of the mutant kinase, or non-cell autonomously from upregulated expression of an activating ligand, such as TNFα (Supplementary Figure S1 ). Both of these processes may be occurring simultaneously in MF and sAML. IKK1 and p65/RELA are substrates of activating phosphorylation by AKT, S6K and PIM kinases, which can be upregulated or activated downstream of activated JAK2 (Supplementary Figure S1 ). 50, 51 Likewise, circulating levels of multiple cytokines, including TNFα, are elevated in MF. 30, 31 Recent studies have shown positive feedback between TNFα and NFκB in AML mouse models, with a combination of proand anti-apoptotic signaling activated by TNFα. 29, 52 Notably, mutations in NFκB pathway genes, while recurrent in several lymphoid neoplasms, appear very rare in myeloid neoplasms. 53, 54 This study illustrates the potential for mass cytometry to identify intracellular signaling phenotypes in cancer. NFκB hyperactivation in MF and sAML was observed throughout early myeloid development, including immunophenotypic hematopoietic stem cell, the population expected to maintain a chronic MPN over a period of years and/or transform to sAML. 27, 55 Evidence of chronic NFκB activation was also identified in T and B cells, in spite of these frequently not being part of the malignant clone. 55 This suggests a cytokine-mediated, non-cell-autonomous component to the NFκB phenotype, which is consistent with the hypothesis that TNFα contributes to malignant clonal dominance in MF 31 and AML. 29, 52 In conclusion, NFκB hyperactivation is widespread in both MF and sAML, both with and without mutation of JAK2. NFκB hyperactivation, and other signaling dysregulations observed, must be considered significant signaling phenotypes in these diseases, which may be important contributors to their pathophysiology. The presence of these signaling phenotypes in HSPC, Figure 7 . Increased NFκB pathway target gene expression in MF. (a) Gene enrichment plots showing relative expression levels in MF versus normal control CD34+ cells. (left to right) Tier 1 (canonical and AML-related NFκB target genes); Tier 1a (canonical and AML-validated NFκB target genes, excluding pro-apoptotic genes); Tier 1b (pro-apoptotic NFκB target genes); Tier 1+2 (known NFκB target genes, including target genes shared with other signaling pathways), FDR q-and FWER, type I false-positive error probability P-values for each gene set are shown. Gene lists are in Supplementary Table S5 . Gene expression datasets were previously published by Norfo et al. 40 including phenotypic hematopoietic stem cell, suggests potential roles in the development or maintenance of clonal dominance. Alternatively, the NFκB pathway, containing pro-apoptotic and anti-apoptotic components, may protect the malignant clone from pro-apoptotic signals induced by cytokines, to which both malignant and residual non-malignant cells are exposed. Further studies will be needed to elucidate the therapeutic potential of NFκB pathway inhibition in myeloid neoplasms. 
